Financial & Tax Architects LLC Purchases 4,189 Shares of Johnson & Johnson (NYSE:JNJ)

Financial & Tax Architects LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 11.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,362 shares of the company’s stock after acquiring an additional 4,189 shares during the quarter. Johnson & Johnson accounts for 1.5% of Financial & Tax Architects LLC’s portfolio, making the stock its 27th largest position. Financial & Tax Architects LLC’s holdings in Johnson & Johnson were worth $5,753,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in JNJ. Innealta Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $27,000. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson during the 1st quarter valued at about $31,000. MFA Wealth Advisors LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at about $44,000. Finally, Fairfield Financial Advisors LTD bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $46,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group decreased their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Morgan Stanley upped their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.0 %

NYSE:JNJ opened at $167.07 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The stock has a market capitalization of $402.08 billion, a price-to-earnings ratio of 10.42, a PEG ratio of 2.71 and a beta of 0.53. The firm has a 50 day moving average of $160.38 and a 200 day moving average of $154.01.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the business posted $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 2.97%. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.